Age 35 has become a threshold that carries an enormous amount of cultural and medical weight when it comes to fertility. Women are warned about their "biological clock" from their mid-twenties onward. The designation "advanced maternal age" appears on medical charts. And for those trying to conceive after 35, the anxiety about time — and about what's happening to their body — can be overwhelming.
The biology is real: fertility does change meaningfully after 35. But the picture is more nuanced than the alarm-clock metaphor suggests. Many women conceive naturally after 35, after 37, even after 40. The changes in fertility are statistical — they affect population-level probabilities — not a binary switch that flips on your birthday.
Understanding exactly what changes, how the data actually reads, and what options exist will help you navigate this time with more clarity and less fear.
What Biologically Changes at 35
Egg Quantity: The Decline in Ovarian Reserve
Women are born with all the eggs they will ever have — approximately 1–2 million primordial follicles at birth. That number declines continuously throughout life, with no replenishment. By puberty, the number is roughly 300,000–400,000. By the late twenties, it has fallen to around 100,000–200,000. By 35, it has typically declined to around 25,000–30,000, and the decline accelerates from there.
This reduction in ovarian reserve is measured clinically by:
- AMH (anti-Müllerian hormone): Produced by small antral follicles, AMH directly reflects the remaining follicle pool. AMH declines progressively from the mid-twenties onward, with an average decline of approximately 6% per year.
- AFC (antral follicle count): An ultrasound count of visible small follicles at the beginning of a menstrual cycle. Normal AFC for a woman in her early thirties is typically 15–25; at 38, it may be 10–15; at 40, it may be 6–12.
- Day 3 FSH: As the follicle pool shrinks, the pituitary gland sends stronger signals to stimulate what remains. Rising FSH (above 10 mIU/mL by most lab standards) indicates decreasing reserve, though it is a less reliable single marker than AMH.
A low ovarian reserve affects how many eggs can be retrieved in an IVF cycle, but it does not eliminate the possibility of natural conception if ovulation is still occurring regularly.
Egg Quality: The Chromosome Problem
Egg quantity is important, but egg quality is the more clinically critical issue after 35. Specifically, the rate of chromosomal abnormalities (aneuploidy) in eggs increases substantially with age.
Research by Franasiak et al. (2014) published data from over 15,000 IVF cycles with PGT-A testing, revealing the following aneuploidy rates by age:
| Age | Approximate Aneuploidy Rate in Embryos |
|---|---|
| Under 35 | ~40–45% |
| 35–37 | ~50–55% |
| 38–40 | ~60–65% |
| 41–42 | ~70–75% |
| Over 42 | ~80–90%+ |
Aneuploid embryos typically either fail to implant, or implant and miscarry early. This is why miscarriage rates increase with age, and why live birth rates per IVF cycle decline. It is also why a woman of 38 who produces 10 eggs in a stimulation cycle may have only 2–4 euploid (chromosomally normal) embryos.
This age-related aneuploidy increase is a function of the meiotic spindle apparatus in the egg — the cellular machinery that separates chromosomes correctly during cell division. This machinery becomes less reliable with age, leading to unequal chromosome distribution.
FSH Rise and Hormonal Changes
As the follicle pool declines, the pituitary gland compensates by producing more FSH to drive follicular development. Elevated day 3 FSH (above 10–12 mIU/mL depending on the lab) reflects diminishing reserve. Very high FSH (>20 mIU/mL) typically indicates severely reduced reserve.
Estrogen levels also begin to shift in the late thirties as the menstrual cycle may shorten slightly (due to a shorter follicular phase) and eventually become more irregular.
"Advanced Maternal Age": What It Means Medically
The term advanced maternal age (AMA) in obstetrics and reproductive medicine applies to women who will be 35 or older at the time of delivery. It was originally chosen because 35 was the threshold at which the risk of Down syndrome from amniocentesis was roughly equal to the risk of pregnancy loss from the procedure. Diagnostic technology has improved dramatically, but the designation has remained.
In practice, AMA means:
- Recommendation for prenatal genetic screening (cell-free fetal DNA or amniocentesis) at any gestational age
- Slightly increased risk of chromosomal conditions in the baby
- Increased monitoring during pregnancy for maternal complications (gestational hypertension, gestational diabetes, placental issues)
- In fertility practice, an accelerated timeline for evaluation and treatment
It does not mean that conception is unlikely, that pregnancy will be high-risk, or that you need IVF. It means you should be more proactive about evaluation and not wait as long to seek help.
Time-to-Pregnancy Statistics by Age
ASRM data on time-to-pregnancy shows meaningful but not dramatic differences by age for unassisted conception:
| Age Group | % Conceiving Within 12 Months |
|---|---|
| 20–24 | ~93% |
| 25–29 | ~90% |
| 30–34 | ~85% |
| 35–39 | ~78% |
| 40–44 | ~65% (within 12 months) |
These numbers include couples who needed medical assistance, not just those who conceived naturally. The key takeaway: the majority of women in their mid-to-late thirties do conceive, but time-to-pregnancy is longer and the rate of needing help is higher.
Testing Recommendations After 35
If you are over 35 and actively trying to conceive, the following testing baseline is reasonable to discuss with your OB-GYN or reproductive endocrinologist:
Ovarian reserve:
- AMH blood test
- Day 3 FSH and estradiol
- Antral follicle count (transvaginal ultrasound)
Uterine evaluation:
- Pelvic ultrasound (baseline)
- Saline infusion sonohysterogram (SIS) or hysteroscopy if there is any concern about the uterine cavity
Partner evaluation:
- Semen analysis (always evaluate both partners)
General:
- TSH (thyroid function)
- Rubella immunity, varicella immunity
- STI screening
These tests can often be ordered by your OB-GYN as a first step before referral to a reproductive endocrinologist.
Trying to Conceive at Home?
If you are in the earlier stages of trying and supplementing timed intercourse with home insemination, MakeAMom offers reusable at-home insemination kits for couples and individuals — the CryoBaby for frozen or low-volume sperm, the Impregnator for low-motility sperm, and the BabyMaker for those with sensitivities. All ship discreetly and are designed for use without a clinic visit.
Explore home insemination kits at MakeAMom →
When to See a Reproductive Endocrinologist
If you are 35–37: Seek evaluation after 6 months of regular unprotected intercourse without conception (instead of the 12-month guideline for women under 35).
If you are 38 or older: Seek evaluation after 3–6 months of trying, or immediately if there are other known risk factors (prior pelvic surgery, irregular cycles, prior STI, known partner factor).
Immediately regardless of age: If you have known risk factors such as irregular or absent periods, prior diagnosis of PCOS or endometriosis, prior pelvic inflammatory disease, or a prior miscarriage — do not wait.
The reason for the shorter window after 35 is mathematical: at 38, a year of trying without success is a year that matters more than it does at 28, given the rate of age-related egg quality decline.
Treatment Options After 35
Expectant Management
Continuing to try naturally for a limited period (with ovulation tracking, timing optimization, and lifestyle optimization) is appropriate for women in their mid-thirties with normal reserve and no identified pathology. This should not extend past 6 months for women over 35.
Ovulation Induction (OI) with IUI
For women with normal reserve and anatomy, stimulated IUI with letrozole or clomiphene is a reasonable first step if natural conception has not occurred after an appropriate waiting period. Success rates per cycle are approximately 10–15% in women 35–39 with good reserve.
IVF
IVF is more appropriate as a first-line treatment after 35 (compared to under 35) because:
- The per-cycle success rates of IUI decline more with age than IVF success rates do
- IVF can retrieve multiple eggs for banking/freezing
- IVF allows PGT-A testing, which significantly improves outcomes and reduces miscarriage rates in older patients
Success rates for IVF with own eggs by age, per SART 2022 data:
| Age | Live Birth Rate Per Transfer (own eggs) |
|---|---|
| Under 35 | ~50–55% |
| 35–37 | ~40–45% |
| 38–40 | ~28–35% |
| 41–42 | ~18–22% |
| Over 42 | ~8–12% |
PGT-A After 35
PGT-A (preimplantation genetic testing for aneuploidy) screens IVF embryos for chromosomal abnormalities before transfer. For women over 35, PGT-A:
- Identifies euploid embryos, which have significantly higher per-transfer success rates
- Reduces miscarriage risk by avoiding transfer of aneuploid embryos
- Allows single embryo transfer with confidence in embryo quality
- Provides clearer information about how many usable embryos are available
The tradeoff is that PGT-A adds cost ($3,000–$5,000) and requires a biopsy of each embryo. For women over 37, the benefit of avoiding aneuploid transfers generally outweighs the cost and procedural risk.
See our complete guide to egg freezing for more on how egg quality affects freezing outcomes.
Donor Egg IVF
For women with significantly diminished ovarian reserve or multiple failed IVF cycles with poor embryo quality, donor egg IVF offers live birth rates of 55–70% per transfer, largely independent of the recipient's age. The donor's eggs are used instead of the patient's own, which sidesteps age-related egg quality issues.
This option can be emotionally complex to consider but provides the highest success rates for women over 40–42 who are not achieving success with own eggs.
IVF Success Rates by Age: A Realistic Summary
| Age at Retrieval | Average Live Birth Rate Per Cycle (Own Eggs) | Expected Euploid Rate |
|---|---|---|
| <35 | 50–55% | ~55–60% of blastocysts |
| 35–37 | 40–45% | ~45–50% of blastocysts |
| 38–40 | 28–35% | ~35–40% of blastocysts |
| 41–42 | 18–22% | ~25–30% of blastocysts |
| >42 | 8–12% | ~10–20% of blastocysts |
These are per-cycle figures. Cumulative rates across multiple cycles are substantially higher. See our IVF success rates by age guide for a more detailed breakdown.
What Can Improve Outcomes After 35
While egg quality decline cannot be reversed, there are legitimate factors that can optimize outcomes:
Timing precision: Using ovulation predictor kits (OPKs) or monitoring cycles with bloodwork and ultrasound maximizes the chance of intercourse at the right time.
Partner sperm health: Sperm quality matters at every age. A recent semen analysis and, if indicated, sperm DNA fragmentation testing ensures no treatable male factor is being overlooked.
Thyroid optimization: Subclinical hypothyroidism is common and treatable. TSH above 2.5 mIU/L in a patient trying to conceive may warrant treatment — discuss with your doctor.
Lifestyle factors: Smoking is directly toxic to eggs and should be eliminated. Maintaining a healthy weight, minimizing alcohol, and managing stress all contribute to the best possible reproductive environment.
Antioxidant supplementation: Some evidence supports CoQ10 (coenzyme Q10) supplementation for egg quality — the mitochondria in eggs depend on CoQ10 for energy. Doses studied range from 400–800 mg/day. This is not a cure for age-related decline but is a low-risk adjunct with biological plausibility.
Frequently Asked Questions
Q: At what age do chromosomal abnormalities in eggs become a significant concern? A: Chromosomal abnormalities increase at every age, but the rise accelerates noticeably after 35. Research by Franasiak et al. (2014) analyzing over 15,000 IVF cycles with PGT-A testing found aneuploidy rates of approximately 40–45% in embryos from women under 35, rising to 50–55% at ages 35–37, 60–65% at 38–40, and 80–90%+ over age 42. These aneuploid embryos typically fail to implant or result in early miscarriage.
Q: How long should a woman over 35 try before seeing a reproductive endocrinologist? A: Women aged 35–37 should seek evaluation after 6 months of regular unprotected intercourse without conception — not the standard 12-month guideline for women under 35. Women 38 or older should seek evaluation after just 3–6 months of trying, or immediately if there are known risk factors such as irregular cycles, prior pelvic surgery, or a previous diagnosis of PCOS or endometriosis.
Q: What are IVF live birth rates after 35 using own eggs? A: Per SART 2022 data, live birth rates per transfer with own eggs are approximately 40–45% at ages 35–37, 28–35% at ages 38–40, 18–22% at ages 41–42, and 8–12% over age 42. These are per-cycle figures; cumulative rates across multiple cycles are substantially higher.
Q: Does PGT-A testing help women over 35? A: Yes — PGT-A (preimplantation genetic testing for aneuploidy) identifies chromosomally normal embryos before transfer, which significantly improves per-transfer success rates, reduces miscarriage risk, and allows single embryo transfer with greater confidence in embryo quality. The test adds cost ($3,000–$5,000) and requires a biopsy of each embryo, but for women over 37, avoiding aneuploid transfers generally outweighs this expense and procedural consideration.
Q: Can CoQ10 supplementation improve egg quality after 35? A: Some evidence supports CoQ10 supplementation as an adjunct for egg quality — the mitochondria in eggs depend on CoQ10 for energy, and mitochondrial function declines with age. Doses studied range from 400–800 mg/day. CoQ10 is a low-risk supplement with biological plausibility, though it is not a reversal of age-related egg quality decline and should be used alongside, not instead of, appropriate medical evaluation.
Key Takeaways
- Fertility after 35 involves real biological changes — particularly declining egg quantity and increasing rates of chromosomal abnormalities in eggs
- AMH and AFC testing can quantify your ovarian reserve; PGT-A in IVF cycles can identify chromosomally normal embryos regardless of age
- Women over 35 should seek evaluation after 6 months of trying (not 12); women over 38 should seek evaluation sooner
- IVF success rates decline with age but remain meaningful through the late thirties; donor eggs offer high success rates for those who cannot succeed with own eggs
- Cumulative success rates across multiple cycles are substantially higher than per-cycle rates — persistence with appropriate evaluation and adjustment matters
This article is for informational purposes only and does not constitute medical advice. Please consult a board-certified reproductive endocrinologist for personalized guidance.
